Результаты поиска

Thai Osteoporosis Foundation (TOPF) position statements on management of osteoporosis.

The adjusted incidence rate of hip fracture in Thailand has increased more than 31% from 1997 to 2006. Mortality and morbidity after hip fra … ecologists and Obstetricians, Physiatrists, Radiologists and 2 Associations of Endocrinologists and Rheumatologists which have involved in the management of patients with osteoporosis.

Bisphosphonates and osteonecrosis of the jaw: a case report.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Semin Arthritis Rheum. 2002;32:94–124. 27. Carter G, Goss AN, Doecke C. Bisphosphonates and avascular necrosis of the jaw: a possible association. Med J Aust. 2005;182:413–5. doi: 10.5694/j.1326-5377.2005.tb06761.x. 28. Ficarra G, Beninati F, Rubino I, Vannucchi A, Longo G, Tonelli P, et al. …

CAR T-клеточная терапия для неврологических расстройств: научное обоснование и механистические исследования.

Разработка и успешное клиническое применение инженерных Т-клеток, содержащих синтетические химериковые антигенные рецепторы (CARs), является важной вехой в лечении рака. Этот подход оптимизирует физиологическую активацию в виво Т-клеток в отношении конкретных целевых антигенов, выраженных на определенных поднаборах клеток, с целью их глубокого и устойчивого истощения. Значительный прогресс был достигнут в реорганизации зданий ЦАР-Т-клеток в целях повышения безопасности, терапевтической эффективности и доступности. Усилия также были сосредоточены на рационализации обрабатывающей промышленности

Совпадение в полном тексте источника
… Ann Rheum Dis 2025 ; 84 ( 7 ): 1284 – 1286 . 40312206 10.1016/j.ard.2025.03.018 23 Motte J Klimas R Sgodzai M , et al . CD19-targeted CAR T-cell therapy for treatment-refractory autoimmune neuropathies . … Rheum Dis Clin N Am 2020 ; 46 ( 3 ): 429 – 444 . 10.1016/j.rdc.2020.03.001 32631598 126 Pérez González A Pellín Jou C Palomo L , et al . Prevalence, dynamics and clinical significance of clonal hematopoiesis of indeterminate potential (CHIP) in newly diagnosed cancer patients . …

Research progress on the clinical application and mechanism of iguratimod in the treatment of autoimmune diseases and rheumatic diseases.

Autoimmune diseases are affected by complex pathophysiology involving multiple cell types, cytokines, antibodies and mimicking factors. Different drugs are used to improve these autoimmune responses, including nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, antibodies, and small molecule drugs (DMARDs), which are prevalent clinically in the treatment of rheumatoid arthritis (RA), etc. However, low cost-effectiveness, reduced efficacy, adverse effects, and patient non-response are unattractive factors driving the development of new drugs such as iguratimod. As a new disease-modi…

Myelodysplasia in VEXAS syndrome.

AbstractVEXAS (vacuoles, E1 enzyme, X linked, autoinflammatory, somatic) syndrome is a clonal hematoinflammatory disorder affecting older, predominantly male patients, characterized by systemic inflammation and progressive bone marrow failure. It is caused by somatic mutations in ubiquitin-activating enzyme E1 (UBA1), an X-linked gene, essential for initiating cellular ubiquitination. Loss-of-function mutations, most commonly M41 missense variants, lead to decreased expression of the cytoplasmic isoform, UBA1b, resulting in accumulation of misfolded proteins and activation of the endoplasmic r

Совпадение в полном тексте источника
… management of VEXAS developed by the International VEXAS Working Group expert panel Arthritis Rheumatol 78 3 2025 509 522 40787890 10.1002/art.43287 PMC12991921 19 Turturice BA Fike A Patel BA Disease trajectories and glucocorticoid exposure in VEXAS syndrome treated with cytokine-directed therapies Ann Rheum … C VEXAS syndrome: complete molecular remission after hypomethylating therapy Ann Hematol 103 3 2024 993 997 38214707 10.1007/s00277-023-05611-w PMC10866742 63 Hadjadj J Nguyen Y Mouloudj D FRENVEX Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX Ann Rheum …

Mobilizing stem cells and inhibition of autoimmunity synergistically modify autoimmune disease to relieve pain: a potential MRG-001 therapy for rheumatoid arthritis.

OBJECTIVES: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent synovial inflammation, bone erosion, cartilage destruction, and debilitating pain. Current therapies often fall short in preventing structural damage and restoring immune balance. To address these limitations, we evaluated MRG-001 - a fixed-dose combination of plerixafor (AMD3100) and low-dose tacrolimus (FK506) with reported immunoregulatory and regenerative potential - in preclinical models of RA. METHODS: The therapeutic efficacy of MRG-001 was assessed in collagen-induced arthritis and collag…

Paraneoplastic Syndrome After Kidney Transplantation: Frequency, Risk Factors, Differences to Paraneoplastic Occurrence of Glomerulonephritis in the Native Kidney, and Implications on Long-Term Kidney Graft Function.

Posttransplant malignancies are an important complication of solid organ transplantation. Kidney transplant recipients are at particularly high risk of cancer development. The most relevant risk factors of carcinogenesis are the use of immunosuppressive agents and oncogenic viral infections. Additionally, immune dysregulation caused by these factors may predispose to various types of organ damage. Paraneoplastic glomerular diseases are one of the most interesting and understudied cancer manifestations. The appropriate diagnosis of paraneoplastic glomerular damage can be challenging in kidney t

Совпадение в полном тексте источника
… Semin Arthritis Rheum ( 2000 ) 29 : 360 – 7 . 10.1053/sarh.2000.6988 10924021 70. Lien Y-HH Lai L-W . Pathogenesis, Diagnosis and Management of Paraneoplastic Glomerulonephritis . Nat Rev Nephrol ( 2011 ) 7 : 85 – 95 . 10.1038/nrneph.2010.171 21151207 PMC3058941 71. … Ann Rheum Dis ( 2017 ) 76 : 1064 – 9 . 10.1136/annrheumdis-2016-209925 27899372 73. Haskell LP Fusco MJ Wadler S Sablay LB Mennemeyer RP . Crescentic Glomerulonephritis Associated With Prostatic Carcinoma: Evidence of Immune-Mediated Glomerular Injury . …

The Rationale for Using Neridronate in Musculoskeletal Disorders: From Metabolic Bone Diseases to Musculoskeletal Pain.

Neridronate or ((6-amino-1-hydroxy-1-phosphonohexyl) phosphonic acid) is an amino-bisphosphonate (BP) synthetized in Italy in 1986. Bisphosp … ue safety and efficacy profile, neridronate has been used in secondary osteoporosis due to genetic, rheumatic, and oncological diseases, including in pediatric patients. In the last decade, this drug has also been studied in chronic musculoskeletal pain conditions, such as algodystrophy, demonstrating effectiveness in improving extraskeletal outcomes. T …

Amyloidosis with Cardiac Involvement: Identification, Characterization, and Management.

Purpose of reviewAmyloidosis is a protein deposition disease whereby a variety of precursor proteins form insoluble fibrils that deposit in tissues, causing organ dysfunction and, many times, death. Accurate characterization of the disease based on the nature of the precursor protein, organ involvement, and extent of disease is paramount to guide management. Cardiac amyloidosis is critical to understand because of its impact on prognosis and new treatment options available.Recent findingsNew imaging methods have proven to be considerably valuable in the identification of cardiac amyloid infilt

Совпадение в полном тексте источника
… Rheum Dis Clin N Am. 2018;44(4):585–603. doi: 10.1016/j.rdc.2018.06.004. 17. Adams D, Koike H, Slama M, Coelho T. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol. 2019;15(7):387–404. doi: 10.1038/s41582-019-0210-4. 18. … Arthritis Rheum. 2006;54(6):2015–2021. doi: 10.1002/art.21902. 43. Quarta CC, Gonzalez-Lopez E, Gilbertson JA, Botcher N, Rowczenio D, Petrie A, Rezk T, Youngstein T, Mahmood S, Sachchithanantham S, Lachmann HJ, Fontana M, Whelan CJ, Wechalekar AD, Hawkins PN, Gillmore JD. …

Mechanism and therapeutic potential of traditional Chinese medicine extracts in sepsis.

Sepsis is a complex syndrome characterized by multi-organ dysfunction, due to the presence of harmful microorganisms in blood which could cause mortality. Complications associated with sepsis involve multiple organ dysfunction. The pathogenesis of sepsis remains intricate, with limited treatment options and high mortality rates. Traditional Chinese medicine (TCM) has consistently demonstrated to have a potential on various disease management. Its complements include reduction of oxidative stress, inhibiting inflammatory pathways, regulating immune responses, and improving microcirculation. Tra

Совпадение в полном тексте источника
… Hsiao | Patients with sepsis | 1.0, 2.0, 3.0 g/time/d | ↑: CD4 + , CD4 +/CD8+ ↓: CD8 + , NK cell | NA | NA | Xu et al. (2022c) Rhubarb preparation | Rheum palmatum L. | Patients with sepsis | 50 g in 50 mL Physiological saline (2 times/d) | ↓: TNF-α, IL-6, IL-1β ↑: IL-10, CD4+/CD8+, HLA-DR/CD4+ | NA … palmatum L. | Male Tuck-Ordinary mice with cerebrovascular thrombosis model | 4 mg/kg | ↓: TNF-α, IL-1β ↑: SOD, PT, aPTT | Heart | NA | Nemmar et al. (2015) Emodin-6- O -b-D-glucoside | Rheum palmatum L. | CLP-induced male C57BL/6 mice | 0.1, 0.2, 0.5, 1, 2, 5, 10 μM | ↓: TACE, EPCR, p38, ERK1/2, JNK …

Pathogenetic Mechanisms Linking Sarcoidosis to Lymphoma.

Sarcoidosis and lymphoma share immunopathological characteristics that suggest a complex, interconnected relationship. This article examines the multi-faceted mechanisms linking sarcoidosis to lymphoma, a phenomenon called sarcoidosis-lymphoma syndrome (SLS). SLS is hard to diagnose, requiring distinct criteria and imaging to differentiate overlapping features and histological differences. The co-occurrence of these diseases may be explained by genetic predispositions, immune dysregulation, and environmental factors that enhance malignancy risk. In active sarcoidosis, chronic inflammation and

Совпадение в полном тексте источника
… Rheum. Dis. 2009 68 648 653 10.1136/ard.2007.085852 18467516 95. Wolfe F. Michaud K. Lymphoma in rheumatoid arthritis: The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients Arthritis Rheum. 2004 50 1740 1751 10.1002/art.20311 15188349 96. Wolfe F. Michaud K. … The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation Arthritis Rheum. 2007 56 1433 1439 10.1002/art.22579 17469100 97. Dahmus J. Rosario M. Clarke K. …

VEXAS Syndrome: A Comprehensive Review of Current Therapeutic Strategies and Emerging Treatments.

VEXAS syndrome is a recently identified autoinflammatory disorder resulting from somatic mutations in the UBA1 gene, leading to a complex spectrum of severe inflammatory and hematologic manifestations. The absence of established treatment guidelines and the variability in clinical presentation make its management particularly challenging. Current therapeutic approaches are often based on limited evidence, and their effectiveness remains inconsistent. This review seeks to consolidate the existing knowledge on therapeutic strategies for VEXAS syndrome, offering a critical evaluation of their eff

Совпадение в полном тексте источника
… Rheum. Dis. 2021;80:1057–1061. doi: 10.1136/annrheumdis-2021-220089. 15. Templé M., Duroyon E., Croizier C., Rossignol J., Huet T., Friedrich C., Zalmai L., Priollet P., Hayem G., Tournillhac O., et al. Atypical splice-site mutations causing VEXAS syndrome. … Rheum. Dis. 2024;83:1358–1367. doi: 10.1136/ard-2024-225640. 64. Salehi T., Callisto A., Beecher M.B., Hissaria P. Tofacitinib as a biologic response modifier in VEXAS syndrome: A case series. Int. J. Rheum. Dis. 2023;26:2340–2343. doi: 10.1111/1756-185X.14785. 65. …

The Production Processes and Biological Effects of Intravenous Immunoglobulin.

Immunoglobulin is a highly diverse autologous molecule able to influence immunity in different physiological and diseased situations. Its effect may be visible both in terms of development and function of B and T lymphocytes. Polyclonal immunoglobulin may be used as therapy in many diseases in different circumstances such as primary and secondary hypogammaglobulinemia, recurrent infections, polyneuropathies, cancer, after allogeneic transplantation in the presence of infections and/or GVHD. However, recent studies have broadened the possible uses of polyclonal immunoglobulin showing that it ca

Совпадение в полном тексте источника
… Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: An open study with thirty-five adult patients Arthritis Rheum. 2002 46 467 474 10.1002/art.10053 11840450 121. Cherin P. Piette J.C. Wechsler B. Bletry O. Ziza J.M. Laraki R. Godeau P. … Arthritis Rheum. 2000 29 321 327 10.1016/S0049-0172(00)80018-9 10805356 148. Sherer Y. Levy Y. Shoenfeld Y. Intravenous immunoglobulin therapy of antiphospholipid syndrome Rheumatology 2000 39 421 426 10.1093/rheumatology/39.4.421 10817776 149. Konova E. …

МикроРН в связи с иммунными заболеваниями: механизм, функции и терапевтические аспекты.

МикроРНК (миРНК) представляют собой эволюционно сохранившиеся, некодирующие молекулы РНК приблизительно 18-25 нуклеотидов по длине, которые регулируют генное выражение на посттранарном уровне. Их главным механизмом действий является пост-ранарное заглушение генов с помощью интерференции РНК, которое достигается путем привязки к дополнительным последовательности в рамках целевых посыльных РНК (mRNA). Накопляемые данные свидетельствуют о ключевой роли miRNA в развитии, дифференциации и функционировании иммунных клеток, а также в сохранении иммунной гомеостазии. Более полное понимание сложных мол

Совпадение в аннотации оригинала
MicroRNAs (miRNAs) are evolutionarily conserved, non-coding RNA molecules approximately 18-25 nucleotides in length that regulate gene expre … enesis and biological functions of miRNAs and examine their regulatory roles in the pathogenesis of rheumatoid arthritis (RA), inflammatory bowel disease (IBD), multiple sclerosis (MS), psoriasis, systemic lupus erythematosus (SLE), and atopic dermatitis (AD). We are also evaluating the potential of these miRNAs as diagnostic and prognostic biomarkers, …

The versatile emodin: A natural easily acquired anthraquinone possesses promising anticancer properties against a variety of cancers.

Cancers are generally recognized as the leading cause of death and a predominant barrier to prolonging life expectancy in both developed and developing countries. Emodin is a typical anthraquinone derivative from various plants that exhibits a wide spectrum of biological activities, such as anticancer, antibacterial, hepatoprotective and anti-inflammatory activities. Much previous preclinical evidence has demonstrated that emodin exhibits reliable effects on several cancer types, including lung cancer, liver cancer, colon cancer, breast cancer, pancreatic cancer, leukemia, cervical cancer, and

Совпадение в полном тексте источника
… Resources of emodin Emodin is a time-honored natural compound that was first reported from plants of the Rheum genus by von Warren de la Rue and Hugo Nuller in the year of 1857 23 . … Emodin commonly exists abundantly in plants of the Polygonaceae family, such as Polygonum multiflorum , Rheum palmatum , Rheum tanguticum , Rheum officinale , Polygonum Cuspidatum , Rumex japonicus , Rumex hydrolapathum , Rumex scutatus , Rumex confertus, Rumex altissimus , Rumex crispus , Rumex stenophyllus …

Equipoise, design bias, and randomized controlled trials: the elusive ethics of new drug development.

The concept of 'equipoise', or the 'uncertainty principle', has been represented as a central ethical principle, and holds that a subject may be enrolled in a randomized controlled trial (RCT) only if there is true uncertainty about which of the trial arms is most likely to benefit the patient. We sought to estimate the frequency with which equipoise conditions were met in industry-sponsored RCTs in rheumatology, to explore the reasons for any deviations from equipoise, to examine the concept of 'design bias', and to consider alternative ethical formulations that might improve subject safety a…

Percutaneous vertebroplasty for painful spinal metastasis: a good option for better quality of life.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Ann Rheum Dis. 2003;62:85–86. doi: 10.1136/ard.62.1.85. 15. Cloft HJ, Jensen ME. Kyphoplasty: an assessment of a new technology. AJNR Am J Neuroradiol. 2007;28:200–203. 16. Mathis JM. Percutaneous vertebroplasty or kyphoplasty: which one do I choose? …

Clinical applications of immunoglobulin: update.

Human immunoglobulin is the most used blood product in the clinical practice. Immunoglobulin applications have increased quickly since the elucidation of its immunomodulatory and antiinflammatory properties which turned this blood product into a precious tool in the treatment of numerous diseases that present with humoral immune deficiency or that cause immune system dysfunction. Currently, the approved indications for Ig are: primary immunodeficiencies, secondary immunodeficiencies (multiple myeloma or chronic lymphoid leukemia), Kawasaki syndrome, immune thrombocytopenic purpura, Guillain Ba

Совпадение в полном тексте источника
… Arthritis Rheum . 2002 ; 46 ( 2 ): 467 - 74 11840450 10.1002/art.10053 85 Jayne DR Lockwood CM Pooled intravenous immunoglobulin in the management of systemic vasculitis . … Arthritis Rheum . 2008 ; 58 ( 1 ): 308 - 17 18163506 10.1002/art.23147 88 Levy Y Sherer Y George J Rovensky J Lukac J Rauova L et al Intravenous immunoglobulin treatment of lupus nephritis . …

Autoimmune Neuromuscular Disorders at a Molecular Crossroad: Linking Pathogenesis to Targeted Immunotherapy.

Myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and idiopathic inflammatory myopathies are among the most widely recognized autoimmune neuromuscular disorders. Although they differ in clinical presentation, shared immunopathogenic mechanisms place them at a molecular crossroads. Evidence of overlapping pathways has led to the development of targeted strategies including complement inhibition, FcRn antagonism, B-cell depletion, and the CAR-T cell approach. In this review, we analyze current knowledge regarding pathogenic mechanisms and their link to immunotherapy, extensiv

Совпадение в полном тексте источника
… Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy Arthritis Rheum. 2011 63 713 721 10.1002/art.30156 21360500 PMC3335400 51. Allenbach Y. Arouche-Delaperche L. Preusse C. Radbruch H. Butler-Browne G. Champtiaux N. … Rheum. Dis. 2025 84 307 318 10.1136/ard-2024-225732 39919903 PMC11822226 56. Knauss S. Preusse C. Allenbach Y. Leonard-Louis S. Touat M. Fischer N. Radbruch H. Mothes R. Matyash V. Böhmerle W. PD1 pathway in immune-mediated myopathies: Pathogenesis of dysfunctional T cells revisited Neurol. …

Treating Protein Misfolding Diseases: Therapeutic Successes Against Systemic Amyloidoses.

Misfolding and extracellular deposition of proteins is the hallmark of a heterogeneous group of conditions collectively termed protein misfolding and deposition diseases or amyloidoses. These include both localized (e.g. Alzheimer's disease, prion diseases, type 2 diabetes mellitus) and systemic amyloidoses. Historically regarded as a group of maladies with limited, even inexistent, therapeutic options, some forms of systemic amyloidoses have recently witnessed a series of unparalleled therapeutic successes, positively impacting on their natural history and sometimes even on their incidence. I

Совпадение в полном тексте источника
… Arthritis Rheum. 65 (4), 1116–1121. 10.1002/art.37827 Lane T., Pinney J. H., Gilbertson J. A., Hutt D. F., Rowczenio D. M., Mahmood S., et al. (2017. a). Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre. … Rheum. Dis. Clin. North Am. 44 (4), 585–603. 10.1016/j.rdc.2018.06.004 Penchala S. C., Connelly S., Wang Y., Park M. S., Zhao L., Baranczak A., et al. (2013). AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proc. Natl. …